News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
21Shares Signals Incoming XRP Supply Shock. Here’s What Happened
TimesTabloid·2026/04/13 17:33
Dow Jones Industrial Average edges lower as Goldman drags, Crude Oil climbs back over $100
101 finance·2026/04/13 17:27
Crypto-aligned super PAC begins to endorse candidates for US midterms
Cointelegraph·2026/04/13 17:03
XRP Braces for a Brutal April Collision as CLARITY Act Hopes Meet Strait of Hormuz Chaos
Tipranks·2026/04/13 16:33
PrivaseaAI (PRAI) fluctuates 56.4% in 24 hours: Low liquidity speculative trading dominates
Bitget Pulse·2026/04/13 16:02
ENJ (EnjinCoin) fluctuated by 54.0% in 24 hours: Short squeeze and GameFi rotation drive the movement
Bitget Pulse·2026/04/13 16:02
AIO (OlaXBT) fluctuated 40.5% within 24 hours: trading volume surged 280% and derivatives OI soared
Bitget Pulse·2026/04/13 16:02
Flash
22:24
International Paper has announced plans to cease its preprint operations in Ridgewood, Kentucky by the end of the third quarter in 2026, and simultaneously close three plants.This move marks a significant adjustment in the company's operational structure.
22:23
According to the Chinese Ambassador to Canada, Canada's annual crude oil supply to China is expected to increase from 15.5 million tons last year to nearly 22 million tons.This potential growth reflects the possibility of further deepening cooperation between China and Canada in the energy sector. If achieved, it would significantly increase Canada's share of crude oil in the Chinese market and have a certain impact on the global energy trade pattern.
22:23
Viridian Therapeutics announced that its innovative drug Lumvoa™ (generic name: veligrotug-vvze) has been approved by the U.S. Food and Drug Administration (FDA) and officially launched for the treatment of Thyroid Eye Disease (TED).This approval marks a significant advancement for Viridian Therapeutics in the field of ophthalmic treatments. Lumvoa™ is a biologic targeting specific targets, and its approval offers a new treatment option for patients with thyroid eye disease. Thyroid eye disease is an autoimmune disorder associated with thyroid dysfunction, causing symptoms such as eye protrusion, double vision, impaired vision, and others, which severely impact patients' quality of life. The launch of this new drug is expected to address unmet medical needs in this disease area.The company stated it will promptly initiate the commercialization process for Lumvoa™ in the United States, ensuring that the drug can benefit patients in need as soon as possible. This approval is based on multiple clinical study data, which demonstrate the effectiveness and safety of the therapy in improving disease signs and symptoms.
News